



NAVANA PHARMA

NAVANA PHARMACEUTICALS PLC.

Corporate Office:
99 Gulshan Avenue, Rupayan Golden Age, 6th Floor, Plot-6, Block-CWN(C), Dhaka-1212.

PRICE SENSITIVE INFORMATION

This is for kind information to all valued shareholders of Navana Pharmaceuticals PLC. and stakeholders that the Board of Directors of the company in its 62nd meeting held on 13th November, 2025 ended at 4.00 p.m. has considered and approved, among others, the Un-Audited Financial Statements for the first quarter (Q1) period ended on September 30, 2025 and took the following Price Sensitive Decision:-

Comparative Statement on Un-Audited Financial Statement for the first quarter (Q1) of financial year-2025-2026 period ended on September 30, 2025:

Sl. No	Particulars	01.07.2025 - 30.09.2025	01.07.2024 - 30.09.2024
I	Earnings Per Share (EPS)	1.71	1.25
		1.69 (Diluted)	
ii	Net Operating Cash Flow Per Share (NOCFPS)	5.08	2.00
		As at 30.09.2025	As at 30.06.2025
iii	Net Asset Value (NAV)	5,051,973,300	4,864,919,142
iv	Net Asset Value Per Share	47.03	45.29

Notes:

- ❖ **Reasons of significant deviation in Earning per share (EPS) & Net Operating Cash Flow per Share (NOCFPS) between the quarterly periods:**
 - EPS: Net Profit after Tax has increased significantly due to the increment of Net Sales & Gross Profit as well as reduction of finance cost, as a result Earnings per Share (EPS) increased by 62.40% from the previous year.
 - NOCFPS: Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 5.08 from Tk. 2.00, because of cash received from the customers was higher than the cash payment to the vendors & others in the reporting period.
- ❖ In compliance with the Dhaka & Chittagong Stock Exchange (Listing) Regulation, 2015, the company is pleased to publish the Un-Audited Financial Statement for the first quarter (Q1) period ended on September 30, 2025 in two widely circulated daily newspapers (one in Bengali and other one in English) and also in an online news portal. The detail of the published quarterly Financial Statements will be available in the website (www.navanapharma.com) of the company.

Dated: November 13, 2025

By order of the Board
Sd/-
Lorens Shamol Mollick FCS
Company Secretary